Guard Therapeutics International AB (publ) (STO:GUARD)

Market Cap	28.23M -92.9%
Revenue (ttm)	n/a
Net Income	-80.99M
EPS	-4.05
Shares Out	20.17M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,380
Open	1.350
Previous Close	1.400
Day's Range	1.350 - 1.500
52-Week Range	0.881 - 27.000
Beta	-0.18
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 19, 2026

About STO:GUARD

Guard Therapeutics International AB (publ), a clinical-stage biotechnology company, develops novel therapies for diseases with high unmet medical need, primarily focusing on various forms of kidney disease in Sweden. The company’s pipeline products include RMC-035, an intact therapeutic A1M protein, that is in a Phase 2b clinical trial for kidney protection with open-heart surgery; in Phase 2a clinical trial for kidney transplantation; and is in a preclinical trial to treat sepsis. It also develops GTZ peptides, a modified A1M-derived peptide w...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2008
• Employees: 12
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: GUARD

Financial Performance

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jul 24, 2026

Data Sources Report a data error